Amphastar Pharmaceuticals (AMPH) Current Leases (2019 - 2026)

Amphastar Pharmaceuticals has reported Current Leases for 8 years, with the latest figure at $8.8 million in Q2 2026.

• On a quarterly basis, Current Leases rose 11.69% year-over-year to $8.8 million in Q2 2026; TTM through Jun 2026 was $8.8 million, a 11.69% increase from a year earlier, with the FY2025 full-year figure at $7.9 million, up 16.52% from the prior year.
• Current Leases was $8.8 million for Q2 2026 at Amphastar Pharmaceuticals, down from $9.7 million in the prior quarter.
• The five-year high for Current Leases was $9.7 million in Q1 2026, with the low at $3.0 million in Q1 2023.
• Average Current Leases over 5 years is $5.3 million, with a median of $4.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Current Leases retreated 11.43% in 2022, then surged 97.17% in 2025.
• Over 5 years, Current Leases stood at $3.0 million in 2022, then jumped by 30.07% to $3.9 million in 2023, then soared by 74.19% to $6.8 million in 2024, then grew by 16.52% to $7.9 million in 2025, then increased by 11.0% to $8.8 million in 2026.
• The last three Current Leases figures came in at $8.8 million (Q2 2026), $9.7 million (Q1 2026), and $7.9 million (Q4 2025), per Business Quant data.